Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Long-Term Debt Repayments (2016 - 2025)

IGC Pharma (IGC) has disclosed Long-Term Debt Repayments for 13 consecutive years, with $3000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed 0.0% to $3000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$3000.0, a 0.0% change, with the full-year FY2025 number at -$3000.0, changed 0.0% from a year prior.
  • Long-Term Debt Repayments was $3000.0 for Q3 2025 at IGC Pharma, up from -$1000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $4000.0 in Q4 2022 to a low of -$5000.0 in Q1 2022.
  • A 5-year average of -$666.67 and a median of -$1000.0 in 2022 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 300.0% in 2022; the steepest drop was 200.0% in 2022.
  • IGC Pharma's Long-Term Debt Repayments stood at $1000.0 in 2021, then skyrocketed by 300.0% to $4000.0 in 2022, then plummeted by 75.0% to $1000.0 in 2023, then tumbled by 600.0% to -$5000.0 in 2024, then skyrocketed by 160.0% to $3000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Long-Term Debt Repayments are $3000.0 (Q3 2025), -$1000.0 (Q2 2025), and -$5000.0 (Q4 2024).